GLP-1 Agonists: Separating Fact from Fiction with Sean Wharton, MD, PharmD, Part 2| Ep502

Could medications originally designed for diabetes actually help treat addiction, eating disorders, and the biology of cravings?

In this part 2 of 2-part episode of Succeed In Medicine Podcast, Dr. Bradley Block sits down with Dr. Sean Wharton, to dig deeper into the science, myths, and emerging uses of GLP-1 agonists. Dr. Wharton explains that these medications don’t simply reduce appetite, they calm what he calls “food noise,” the constant mental pull toward eating that many people with obesity experience. This neurological effect has opened the door to exciting possibilities: early research suggests GLP-1 drugs may also reduce cravings for alcohol and other addictive behaviors. Dr. Wharton also clarifies the confusing world of brand names. Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are tirzepatide. The differences are largely about FDA indications and insurance coverage, not completely different medications.

The episode tackles common fears patients and clinicians hear every day. Do these medications cause eating disorders? No, in fact, they may help treat them. Are the side effects dangerous? Usually not, and most are manageable with proper dosing. Is “Ozempic face” real? It’s simply normal fat loss, not a drug-specific problem. Most importantly, Dr. Wharton reinforces a compassionate, evidence-based message: obesity is a chronic, biological disease, and GLP-1 medications are tools to treat it, just like medications for blood pressure or diabetes.

Three Actionable Takeaways

• GLP-1 Medications Affect the Brain as Much as the Stomach: These drugs reduce “food noise” and cravings, helping patients regain control over eating behaviors. Their impact is neurological, not simply about willpower or restriction.
• Side Effects Are Real—but Usually Manageable: Nausea, constipation, and GI symptoms are the most common issues, especially early on. Starting low and increasing doses slowly makes treatment far more tolerable.
• Treatment Decisions Should Be Individualized: Not every patient must stay on these medications forever. Conversations about duration, goals, and expectations should be collaborative and tailored to each person.

About the Show:

Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!

About the Guest:

Dr. Sean Wharton holds doctorates in Pharmacy and Medicine from the University of Toronto. He is the Director of the Wharton Medical Clinic, a community-based weight management and diabetes clinic, and serves as Assistant Professor at the University of Toronto and Adjunct Professor at McMaster and York Universities.

Dr. Wharton is the lead author of the 2020 Canadian Obesity Guidelines, recognized worldwide, and has published extensively in major medical journals including the New England Journal of Medicine. He is a passionate advocate for health equity and improving the way obesity is understood and treated in healthcare.

LinkedIn: linkedin.com/in/drseanwharton

Website: whartonmedicalclinic.com

About the Host:

Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physicians

Want to be a guest?

Email Brad at [email protected] or visit www.physiciansguidetodoctoring.com to learn more!

Socials:

@physiciansguidetodoctoring on Facebook

@physicianguidetod